Abcellera Biologics Inc (ABCL)
AbCellera Biologics Inc. is a healthcare company focused on discovering and developing antibody-based medicines for diseases with unmet medical needs in the United States. Its pipeline includes ABCL635, a non-hormonal medicine in Phase 2 testing for moderate to severe vasomotor symptoms, and ABCL575, a fully human, half-life extended monoclonal antibody in Phase 1 development for T-cell-mediated autoimmune conditions such as atopic dermatitis. The company has collaboration and license agreements with Eli Lilly and Company and AbbVie Inc., and it also has partnership arrangements involving Viking Global Investors & ArrowMark Partners and Biogen Inc. Founded in 2012, AbCellera is headquartered in Vancouver, Canada.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-ABCL
|
$4.21
|
-29.8% Downside
|
Overvalued
|
$10.50
|
75.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 5, 2026
|
-12.8x
|
2.0x
|
23.2x
|
1.771 B
|
1.374 B
|
7.3%
|
67.2%
|
7.9
|
—
|
131.5%
|
